46 results on '"Wong, D.J."'
Search Results
2. Phase 2 study of intratumoral vidutolimod in combination with intravenous cemiplimab in patients with selected advanced cancer or metastatic cancer: trial in progress
3. A-331 - Phase 2 study of intratumoral vidutolimod in combination with intravenous cemiplimab in patients with selected advanced cancer or metastatic cancer: trial in progress
4. MA07.05 Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
5. Quantification of Temporal Cytopenic Changes during Concurrent Head and Neck Chemoradiation
6. Patient-Reported Quality of Life Outcomes After Integrating Exclusive Liquid Meal Replacement in Patients With Head and Neck Cancer Undergoing Chemoradiation: Results From a Phase II Study
7. 927TiP SKYSCRAPER-09: A phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN)
8. LBA47 A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
9. 922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
10. 920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort
11. An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis
12. Combination Immunotherapy and TKI in Metastatic Refractory Thyroid Cancer, a Case Series
13. Distress Screening and Follow-Up Among Patients Within a Multidisciplinary Head and Neck Cancer Program
14. Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour
15. Integrating Exclusive Liquid Meal Replacement Supplementation to Reduce Gastrostomy Tube Rates in Patients with Head and Neck Cancer Undergoing Chemoradiation: Preliminary Results of a Phase II Study
16. Overall responses and survival in RCC on pegilodecakin with anti-PD-1
17. Design and implementation of an RSA cryptosystem using multiple DSP chips
18. IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)
19. Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
20. Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
21. Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
22. Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
23. Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)
24. Developing Supportive Care Services Within a Multidisciplinary Head and Neck Cancer Program
25. Addition of Chemotherapy is Associated With a Survival Detriment for Early Stage (T1-2N0M0) Glottic Squamous Cell Carcinoma Treated With Definitive Radiation Therapy
26. Multi-institutional Analysis of Next Generation Sequencing of Cell Free Circulating Tumor DNA of Blood Samples from Recurrent and Metastatic Head and Neck Cancer Patients
27. Avelumab in patients with metastatic adrenocortical carcinoma (mACC): Results from the JAVELIN solid tumor trial
28. Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update
29. Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)
30. Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer
31. 1493P - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour
32. Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
33. 1144P - Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
34. 1143P - Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)
35. 1130O - Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
36. 1117TiP - IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)
37. 1050PD - Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
38. 1046O - Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
39. 1316P - Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update
40. 913P - Avelumab in patients with metastatic adrenocortical carcinoma (mACC): Results from the JAVELIN solid tumor trial
41. 874P - Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer
42. 744P - Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)
43. Regulation of Extracellular Matrix Deposition and Remodeling During Vein Graft Adaptation
44. 364PD - Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
45. Design and implementation of RSA cryptosystem using multiple DSP chips.
46. Clonal cell populations with p16 lesions arise early and expand within Barrett's metaplastic epithelium
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.